Role of Herbal Immunomodulator (Viranorm) as Add-on Treatment in Asymptomatic or Mildly Symptomatic COVID-19 Confirmed Cases
Keywords:
COVID-19, SARS-CoV-2, immunomodulatory, NLR, LMR, inflammationAbstract
Background: Coronavirus disease 2019 (COVID-19) is a highly infectious disease known to be caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Boosting the immune system seems to be a judicious strategy to combat
the coronavirus infection. Objective: The primary objective of this study was to compare the efficacy and safety of Viranorm +
standard of care with standard care alone in the prevention of disease progression in asymptomatic or mildly symptomatic
COVID-19 infection. Secondary objective was to compare the immunological response of Viranorm + standard of care with
standard care alone in asymptomatic or mildly symptomatic COVID-19 infection. Results: Of the 251 randomized subjects,
a total of 123 received Viranorm + standard of care and 128 received standard of care alone. After administration of study
treatment, on visit 1, follow-up was done on Days 3, 7, 14 and 21. The patients treated with Viranorm + standard of care
showed significantly lesser time to resolution of cough than the patients with standard of care alone. At Day 7 and Day 14,
the reverse transcription polymerase chain reaction (RT-PCR) results were available for only few patients. Therefore, no firm
conclusions can be drawn on the effect of the drug on the incidence of RT-PCR negative subjects. All subjects from both
treatment groups reported recovery and no deaths occurred during the study. At Day 14, neutrophil-to-lymphocyte ratio
(NLR) values decreased in both treatment groups. The magnitude of decrease in NLR was substantially higher in the group
that received Viranorm as an add-on treatment (8% median decrease) compared to the group that received only standard
of care (2.6% median decrease). No adverse events or deaths occurred during the entire study duration. Conclusion: The
add-on treatment with herbal immunomodulator Viranorm for COVID-19 is safe and effective in reducing the duration of
cough and is indicative of a significant decrease in systemic inflammation as shown by NLR.
Downloads
Published
Issue
Section
License
All open access articles published in IJCP are distributed under the terms of the CC BY-NC 4.0 license (Creative Commons Attribution-Non-Commercial 4.0 International Public License). This license permits unrestricted use, distribution, and reproduction of the articles in any medium for non-commercial purposes, provided that: The original authorship is properly and fully attributed. The IJCP is cited as the original place of publication with correct citation details. If an original work is reproduced or disseminated in part or as a derivative work, this must be clearly indicated. No articles are reproduced for commercial use without prior consent from the IJCP. All licensing requests and permissions for commercial use will be managed by the Publisher.
